<DOC>
	<DOCNO>NCT00830674</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability KRN23 single intravenous ( IV ) subcutaneous ( SC ) administration XLH patient .</brief_summary>
	<brief_title>A Study KRN23 X-linked Hypophosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<criteria>1 . 18 year old 2 . Clinical diagnosis XLH 3 . TmP/GFR le 2.0 mg/dL 4 . GFR 60 mL/min 1 . Have sign active infectious disease infection require treatment antibiotic within three week prior screen 2 . History known immunodeficiency 3 . Lactating female , female patient pregnant plan become pregnant study 4 . Use pharmacologic vitamin D metabolite analog , phosphate , calcimimetics , ingestion aluminum hydroxide antacid within 10 day prior screen dose 5 . Use supplement contain phosphate , calcium and/or vitamin D within 10 day prior screen dose 6 . Receipt live ( attenuate ) vaccine within 3months prior screen 7 . Have condition , opinion Investigator , could present concern either patient safety difficulty data interpretation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>XLH</keyword>
</DOC>